27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Higher MCI prevalence was identified in community-dwelling older adult populations in China compared with some other countries, possibly due to more broadened criteria being adopted for confirming the diagnosis. 3 key findings →
Design: systematic review Participants: 112,632 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Although antipsychotics were associated with greater harm than antidepressants and anticonvulsants in subgroups of persons with dementia, medications used in lieu of antipsychotics for treating neuropsychiatric symptoms in dementia, such as anticonvulsants and dextromethorphan-quinidine, were also associated with harm. 5 key findings →
Design: randomized controlled trial Participants: 209 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Studies varied widely in size and quality and therefore we must be circumspect in our conclusions. 3 key findings →
Design: systematic review Participants: 60 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
As one of few meta-analyses comparing different quantities of physical activity and exercise interventions for AD in details, our study suggests that physical activity and exercise can improve cognition of older adults with AD. 4 key findings →
Design: meta-analysis Participants: 673 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
This meta-review supports the conclusion that being a caregiver for people with dementia is associated with psychological stress and physical ill-health. 5 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Previous conclusions of a lack of efficacy for cognitive training in MCI may have been influenced by not clearly defining the intervention. 1 key finding →
Design: systematic review Participants: 305 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
After 3 months, IG improved gait speed (p = 0.016), implying a statistically significant difference between groups in favour of IG (p = 0.003). 3 key findings →
Design: randomized controlled trial Participants: 31 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
MoCA and MMSE were more similar for dementia cases, but MoCA distributes MCI cases across a broader score range with less ceiling effect. 4 key findings →
Design: cross-sectional Participants: 219 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Social isolation was significantly associated with reduced cognitive ability (pooled effect = -0.07, 95% CI = -0.08, -0.05), with consistently negative effects across memory, orientation, and executive ability. 4 key findings →
Design: meta-analysis Participants: 101,581 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Nonlinear dose-response relationship between exercise and cognitive improvement in Alzheimer's disease, with the optimal AE dose identified at 660 METs-min/week for enhancing cognitive function in AD. 3 key findings →
Design: meta-analysis Participants: 2,242 Evidence: early
Full summary, score breakdown and related studies → Original source Free full text
The demographic and health transitions will lead to large and rapid increases in the numbers of dependent older people particularly in middle income countries (MIC). 2 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Depression is linked to an increased risk of cognitive decline and dementia; therefore, failing to diagnose and treat LLD in later life may have significant health implications. 4 key findings →
Design: longitudinal study Participants: 31,464 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Further studies should bridge the gap in understanding and give a more global portrait by adding important personal variables such as dementia, organizational variables such as use of community and primary care, and contextual variables such as social and economic frailty. 5 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Digital RT proved an innovative approach to manage PWD and will thus help PWD achieve a better mood and have more opportunities to engage in social interactions. 3 key findings →
Participants: 25 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Among the 12 biomarkers, only pTau was higher in frail individuals than in their not-frail peers (471.3 ± 58.1 pg/mL vs. 451.9 ± 61.1 pg/mL, p = 0.022). 4 key findings →
Design: longitudinal study Participants: 313 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Data collection began in Ontario and Alberta Canada in June 2015 and is expected to be completed in June 2017. 5 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Of the 18,341 patients, we found that 2202 (12%) were described as "frail" in clinical notes. 5 key findings →
Design: cohort study Participants: 18,341 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
A co-morbidity score was significantly higher in AD participants compared to controls. 3 key findings →
Participants: 187 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
This study compared individuals whose clinical diagnosis of Alzheimer's disease (AD) matched or did not match neuropathologic results at autopsy on clinical and functional outcomes (cognitive impairment, functional status and neuropsychiatric symptoms). 4 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Ultimately, 10,373 participants were included in the analysis. 5 key findings →
Design: longitudinal study Participants: 10,373 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The results demonstrated that CCIs have beneficial effects on domain-specific cognition in people with MCI but no significant effects on people with dementia. 5 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Variation in use of APMs in U.S. nursing homes based upon facility characteristics exemplifies the need for a more systematic protocol guiding the use of these medications, along with heightened regulatory policies and enforcement. 2 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
When poor SRH was present we found no increased risk for NH placement or death among elderly people with mild AD. 3 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Mean total BPSD score was 17.66 ± 20.67, and the mean score for family caregiver burden was 9.65 ± 11.12. 1 key finding →
Participants: 170 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer's disease (AD) is the most frequently occurring type of dementia. 4 key findings →
Participants: 483,507 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled.
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →